Search - tctmd.com

Displaying 21 - 40 of 46

Sort: Relevancy | Date

News Daily News

Hybrid Coronary Revascularization at 5 Years: Similar Outcomes to CABG

Yael L. Maxwell

April 23, 2018

News Conference News TCT 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Michael O'Riordan

October 30, 2017

Presentation CHIP Seattle 2017

How a CHIP Operator Manages Saphenous Vein Graft (SVG) Disease

Presenter: John M. Lasala

August 11, 2017

News Daily News

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

Michael O'Riordan

July 03, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News ESC 2016

BASKET-SAVAGE: DES Reign for Saphenous Vein Graft PCI Amid Declining Use

Shelley Wood

August 31, 2016

Presentation ESC 2016

Drug-Eluting vs Bare Metal Stents in Saphenous Vein Grafts: The Prospective Randomized BASKET-SAVAGE Trial

Presenter: Raban V. Jeger

August 31, 2016

News Opinion Editor's Corner

ESC 2016: Bare-Metal Flashbacks, Coronary Imaging Comparisons, Heart Team Hype, and His Holiness

Shelley Wood

August 24, 2016

Presentation EuroPCR 2016

Sealing Moderate Coronary Saphenous Vein Graft Lesions with Drug-Eluting Stents as a New Approach to Reducing Cardiac Events The VELETI II Randomized Trial

Presenter: Josep Rod?s-Cabau

May 19, 2016

News Conference News EuroPCR 2016

Stent ‘Sealing’ of Nonobstructive Saphenous Vein Graft Plaques Fails to Prevent CV Events

Shelley Wood

May 18, 2016

News Features

From Great to Greater: Innovation in Stent Technology Possible, Worth Pursuing

Todd Neale

November 08, 2015

News Daily News

Study Supports Multiarterial CABG for Multivessel CAD

Todd Neale

September 24, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Daily News

Los SLF y SMD son Ambos Aptos para el Tratamiento de Pacientes con Lesiones IVS

July 20, 2015

News Daily News

DES、BMS 均适合治疗患隐静脉桥血管病变的患者

July 20, 2015

News Daily News

DES, BMS Both Suitable for Treating Patients With SVG Lesions

July 20, 2015

News Conference News EuroPCR 2014

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

Caitlin E. Cox

May 28, 2014

News Daily News

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

Jason Kahn

October 11, 2013

News Daily News

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Jason Kahn

March 06, 2012

Presentation TCT 2012

Prospective Evaluation Of the Xience V Everolimus-Eluting Stent In Saphenous Vein Graft Atherosclerosis: the Xience V-SVG Angiographic Study.

Presenter: Emmanouil S. Brilakis, Aristotelis C. Papayannis, Abdul-rahman R. Abdel-karim, Tesfaldet T. Michael, Arif Mahmood, Lorenza B. Makke, Michele Roesle, Donald Haagen, Bavana V. Rangan, Subhash Banerjee

January 03, 2012

Advertisement

Hybrid Coronary Revascularization at 5 Years: Similar Outcomes to CABG

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

How a CHIP Operator Manages Saphenous Vein Graft (SVG) Disease

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

BASKET-SAVAGE: DES Reign for Saphenous Vein Graft PCI Amid Declining Use

Drug-Eluting vs Bare Metal Stents in Saphenous Vein Grafts: The Prospective Randomized BASKET-SAVAGE Trial

ESC 2016: Bare-Metal Flashbacks, Coronary Imaging Comparisons, Heart Team Hype, and His Holiness

Sealing Moderate Coronary Saphenous Vein Graft Lesions with Drug-Eluting Stents as a New Approach to Reducing Cardiac Events The VELETI II Randomized Trial

Stent ‘Sealing’ of Nonobstructive Saphenous Vein Graft Plaques Fails to Prevent CV Events

From Great to Greater: Innovation in Stent Technology Possible, Worth Pursuing

Study Supports Multiarterial CABG for Multivessel CAD

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

Los SLF y SMD son Ambos Aptos para el Tratamiento de Pacientes con Lesiones IVS

DES、BMS 均适合治疗患隐静脉桥血管病变的患者

DES, BMS Both Suitable for Treating Patients With SVG Lesions

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Prospective Evaluation Of the Xience V Everolimus-Eluting Stent In Saphenous Vein Graft Atherosclerosis: the Xience V-SVG Angiographic Study.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content